At Alector, we are on a mission to slow the progression of neurodegenerative diseases and one day prevent their occurrence.
We are a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Our approach is based on insights into human genetics, immunology and neuroscience. Just as immuno-oncology therapies recruit the peripheral adaptive immune system to counteract tumors, our immuno-neurology therapies target immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders.
The result so far: an industry-leading portfolio of immuno-neurology programs designed to harness the brain’s immune system to fight disease that we are advancing through the clinic independently and with partners.